High affinity antibody antagonists of interleukin-13 receptor alpha 1
View Patent ↗High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
1. A method for ameliorating a condition caused or exacerbated by interleukin 13 receptor alpha 1-mediated activity comprising administering to a subject in need of treatment an effective amount of an antibody comprising
(a) a heavy chain variable comprising CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:121, respectively; and
(b) a light chain variable region comprising CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO:84, SEQ ID NO:85, and SEQ ID NO:122, respectively,
thereby ameliorating the condition caused or exacerbated by interleukin 13 receptor alpha 1-mediated activity, wherein the condition is asthma, allergy, allergic rhinitis, chronic sinusitis, hay fever, atopic dermatitis, chronic obstruction pulmonary disease, pulmonary fibrosis, esophageal eosinophilia, scleroderma, fibrosis, ulcerative colitis, anaphylaxis, or Hodgkin's lymphoma.
2. The method of claim 1 , wherein the antibody comprises
(a) a heavy chain variable comprising CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:7, respectively; and
(b) a light chain variable region comprising CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO:84, SEQ ID NO:85, and SEQ ID NO:38, respectively.
3. The method of claim 2 , wherein the heavy chain variable region of the antibody has the amino acid sequence as set forth in SEQ ID NO:63 and the light chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:71.
4. The method of claim 1 , wherein the condition is asthma.
5. The method of claim 1 , wherein the condition is atopic dermatitis.
6. The method of claim 1 , wherein the condition is chronic obstructive pulmonary disease.
7. The method of claim 2 , wherein the condition is asthma.
8. The method of claim 2 , wherein the condition is atopic dermatitis.
9. The method of claim 2 , wherein the condition is chronic obstructive pulmonary disease.
10. The method of claim 3 , wherein the condition is asthma.
11. The method of claim 3 , wherein the condition is atopic dermatitis.
12. The method of claim 3 , wherein the condition is chronic obstructive pulmonary disease.